Healthcare / Medical DevicesTaipei Exchange
$50.60
-0.10 (-0.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $262.7M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
13.4x
↓EV/EBITDA
4.6x
↓ROE
9.1%
↑Gross Margin
44.1%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.4%
FCF CAGR
+17.4%
FCF margin
18.9%
FCF / Net income
1.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.39B · net income $152.1M · FCF $262.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.39B | $1.39B | $1.57B | $1.59B | $1.29B |
| Net Income | $152.1M | $152.1M | $205.4M | $210.3M | $137.1M |
| EBITDA | $372.1M | $372.1M | $472.9M | $448.7M | $294.9M |
| EPS | — | — | 5.13 | 5.25 | 3.42 |
| Gross Margin | 44.1% | 44.1% | 40.0% | 37.8% | 35.0% |
| Operating Margin | 13.4% | 13.4% | 15.6% | 16.7% | 12.0% |
| Net Margin | 11.0% | 11.0% | 13.1% | 13.2% | 10.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.28 | 0.29 | 0.21 |
| Current Ratio | 1.97 | 1.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $262.7M | $262.7M | $126.5M | $289.1M | $162.2M |
| Returns | |||||
| ROE | 9.1% | 9.1% | 13.4% | 13.7% | 9.9% |
| Valuation | |||||
| P/E | 13.35 | 13.35 | 16.25 | 16.78 | 13.75 |
| EV/EBITDA | 4.58 | 4.58 | 6.43 | 6.78 | 5.06 |
| P/B | 1.21 | 1.21 | 2.17 | 2.30 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | -11.8% | -11.8% | -1.3% | 23.4% | — |
| EPS Growth | — | — | -2.2% | 53.3% | — |
| Dividend Yield | 8.3% | 8.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.3%
Start / end P/E
n/dx → n/dx
EPS bridge
5.13 → n/d
Residual
-32.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.